Bile Diversion Improves Metabolic Phenotype Dependent on Farnesoid X Receptor (FXR)

被引:8
|
作者
Pierre, Joseph F. [1 ,2 ]
Li, Yuxin [3 ]
Gomes, Charles K. [2 ]
Rao, Prahlad [2 ]
Chang, Eugene B. [1 ]
Yin, Deng Ping [3 ]
机构
[1] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA
[2] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA
[3] Univ Chicago, Dept Surg, 5841 S Maryland Ave, Chicago, IL 60637 USA
关键词
Y GASTRIC BYPASS; GLUCOSE-HOMEOSTASIS; INSULIN-RESISTANCE; WEIGHT-LOSS; PPAR-ALPHA; ACID; LIVER; ACTIVATION; OXIDATION; OBESITY;
D O I
10.1002/oby.22440
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The current study investigated whether bile diversion (BD) improves metabolic phenotype under farnesoid X receptor (FXR) deficiency. Methods BD was performed in high-fat diet (HFD)-fed FXR knockout (FXRko) and wild-type (WT) animals. Metabolic phenotypes, circulating enteroendocrine hormones, total bile acids (BAs) and BA composition, and cecal gut microbiota were analyzed. Results FXR-deficient mice were resistant to HFD-induced obesity; however, FXR-deficient mice also developed hyperglycemia and exhibited increased liver weight, liver steatosis, and circulating triglycerides. BD increased circulating total BAs and taurine-b-muricholic acid, which were in line with normalized hyperglycemia and improved glucose tolerance in HFD-fed WT mice. FXR deficiency also increased total BAs and taurine-b-muricholic acid, but these animals remained hyperglycemic. While BD improved metabolic phenotype in HFD-fed FXRko mice, these improvements were not as effective as in WT mice. BD increased liver expression of fibroblast growth factor 21 and peroxisome proliferator-activated receptor gamma coactivator-1 beta and elevated circulating glucagon-like peptide-1 levels in WT mice but not in FXRko mice. FXR deficiency altered gut microbiota composition with a specific increase in phylum Proteobacteria that may act as a possible microbial signature of some diseases. These cellular and molecular changes in FXRko mice may contribute to resistance toward improved metabolism. Conclusions FXR signaling plays a pivotal role in improved metabolic phenotype following BD surgery.
引用
收藏
页码:803 / 812
页数:10
相关论文
共 50 条
  • [21] Human/mouse bile salt export pump promoter is transactivated by farnesoid X-receptor/bile acid receptor (FXR/BAR) in the presence of bile acids
    Ananthanarayanan, M
    Balasubramanian, N
    Mangelsdorf, DJ
    Suchy, FJ
    BIOLOGY OF BILE ACIDS IN HEALTH AND DISEASE, 2001, 120 : 37 - 42
  • [22] Farnesoid X Receptor (FXR) Activation and FXR Genetic Variation in Inflammatory Bowel Disease
    Nijmeijer, Rian M.
    Gadaleta, Raffaella M.
    van Mil, Saskia W. C.
    van Bodegraven, Adriaan A.
    Crusius, J. Bart A.
    Dijkstra, Gerard
    Hommes, Daan W.
    de Jong, Dirk J.
    Stokkers, Pieter C. F.
    Verspaget, Hein W.
    Weersma, Rinse K.
    van der Woude, C. Janneke
    Stapelbroek, Janneke M.
    Schipper, Marguerite E. I.
    Wijmenga, Cisca
    van Erpecum, Karel J.
    Oldenburg, Bas
    PLOS ONE, 2011, 6 (08):
  • [23] Natural Products as Farnesoid X Receptor (FXR) Agonists: Their Interactions with FXR Ligand Binding Region
    Lin, Hsiang-Ru
    MINI-REVIEWS IN ORGANIC CHEMISTRY, 2016, 13 (02) : 97 - 108
  • [24] Dual Targeting of Bile Acid Receptor-1 (TGR5) and Farnesoid X Receptor (FXR) Prevents Estrogen-Dependent Bone Loss in Mice
    Li, Zhenxi
    Huang, Jinping
    Wang, Fanhua
    Li, Wenjun
    Wu, Xian
    Zhao, Chenglong
    Zhao, Jian
    Wei, Haifeng
    Wu, Zhipeng
    Qian, Ming
    Sun, Peng
    He, Liang
    Jin, Yunyun
    Tang, Jie
    Qiu, Wenwei
    Siwko, Stefan
    Liu, Mingyao
    Luo, Jian
    Xiao, Jianru
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (04) : 765 - 776
  • [25] Regulation of bile acids and their receptor FXR in metabolic diseases
    Li, Yao
    Wang, Lulu
    Yi, Qing
    Luo, Linsong
    Xiong, Yuxia
    FRONTIERS IN NUTRITION, 2024, 11
  • [26] Negative-feedback regulation of the ileal apical sodium-dependent bile acid transporter (ASBT) is mediated by the farnesoid x-receptor (FXR)
    Chen, F
    Ma, L
    Ananthanarayanan, M
    Sinal, C
    Dawson, P
    Mangelsdorf, D
    Gonzalez, F
    Shneider, BL
    GASTROENTEROLOGY, 2002, 122 (04) : A625 - A625
  • [27] Medicinal Chemistry and Pharmacological Effects of Farnesoid X Receptor (FXR) Antagonists
    Lamers, Christina
    Schubert-Zsilavecz, Manfred
    Merk, Daniel
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2014, 14 (19) : 2188 - 2205
  • [28] Role of Farnesoid X Receptor (FXR) in control of plasma lipid levels
    Claudel, T
    Elzinga, BM
    Bloks, V
    Staels, B
    Voshol, PJ
    Kuipers, F
    ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 95 - 96
  • [29] Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis
    Moris, Demetrios
    Giaginis, Constantinos
    Tsourouflis, Gerasimos
    Theocharis, Stamatios
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (11) : 1147 - 1157
  • [30] Anthranilic acid derivatives as novel ligands for farnesoid X receptor (FXR)
    Merk, Daniel
    Gabler, Matthias
    Gomez, Roberto Carrasco
    Flesch, Daniel
    Hanke, Thomas
    Kaiser, Astrid
    Lamers, Christina
    Werz, Oliver
    Schneider, Gisbert
    Schubert-Zsilavecz, Manfred
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (08) : 2447 - 2460